Baochun Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8023292/publications.pdf

Version: 2024-02-01

20 papers

2,853 citations

15 h-index 19 g-index

20 all docs

20 docs citations

20 times ranked 5318 citing authors

#	Article	IF	CITATIONS
1	Facts and Hopes in the Relationship of EBV with Cancer Immunity and Immunotherapy. Clinical Cancer Research, 2022, 28, 4363-4369.	3.2	3
2	Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature, 2021, 590, 157-162.	13.7	53
3	Genetic Perturbation of CD70/CD27 Co-Stimulation Promotes the Development of Bcl6-Driven Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 713-713.	0.6	0
4	BCR-dependent lineage plasticity in mature B cells. Science, 2019, 363, 748-753.	6.0	76
5	Signaling by the Epstein–Barr virus LMP1 protein induces potent cytotoxic CD4 ⁺ and CD8 ⁺ T cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E686-E695.	3.3	51
6	Genetic drivers of NF-κB deregulation in diffuse large B-cell lymphoma. Seminars in Cancer Biology, 2016, 39, 26-31.	4. 3	20
7	A Rapid Embryonic Stem Cell–Based Mouse Model for B-cell Lymphomas Driven by Epstein–Barr Virus Protein LMP1. Cancer Immunology Research, 2015, 3, 641-649.	1.6	3
8	An Oncogenic Role for Alternative NF-κB Signaling in DLBCL Revealed upon Deregulated BCL6 Expression. Cell Reports, 2015, 11, 715-726.	2.9	66
9	Regulation of IgD Expression and Its Role in B Cell Transformation. Blood, 2015, 126, 2230-2230.	0.6	1
10	Studying Epstein-Barr Virus Pathologies and Immune Surveillance by Reconstructing EBV Infection in Mice. Cold Spring Harbor Symposia on Quantitative Biology, 2013, 78, 259-263.	2.0	30
11	Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis. Cancer Cell, 2012, 22, 167-179.	7.7	251
12	Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse Model. Cell, 2012, 148, 739-751.	13.5	139
13	Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma. Cancer Cell, 2010, 18, 580-589.	7.7	177
14	Loss of Negative Feedback Control of Nuclear Factor-ÎB2 Activity in Lymphocytes Leads to Fatal Lung Inflammation. American Journal of Pathology, 2010, 176, 2646-2657.	1.9	14
15	PI3 Kinase Signals BCR-Dependent Mature B Cell Survival. Cell, 2009, 139, 573-586.	13.5	564
16	Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature Immunology, 2008, 9, 405-414.	7.0	1,173
17	Constitutive Production of NF-κB2 p52 Is Not Tumorigenic but Predisposes Mice to Inflammatory Autoimmune Disease by Repressing Bim Expression. Journal of Biological Chemistry, 2008, 283, 10698-10706.	1.6	42
18	NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10883-10888.	3.3	97

#	Article	IF	CITATIONS
19	NF-κB2 mutation targets TRAF1 to induce lymphomagenesis. Blood, 2007, 110, 743-751.	0.6	49
20	NF-κB2 Is Required for the Control of Autoimmunity by Regulating the Development of Medullary Thymic Epithelial Cells. Journal of Biological Chemistry, 2006, 281, 38617-38624.	1.6	44